Factors associated with significant liver fibrosis in patients with type 2 diabetes mellitus and metabolic dysfunction-associated steatotic liver disease: a single-center retrospective study
Faktoren, die mit signifikanter Leberfibrose bei Patient:innen mit Typ-2-Diabetes mellitus und metabolic dysfunction-associated steatotic liver disease assoziiert sind: monozentrische retrospektive Studie
Frontiers in Endocrinology · 03.11.2026 · 17
DOI: 10.3389/fendo.2026.2005171 ↗Auf einen Blick
Bei 1.355 stationären Patient:innen mit T2DM und MASLD war signifikante Fibrose häufig. Alter, CAP-Grad, AST, GGT und Hyperurikämie waren positiv assoziiert.
Fragestellung
Welche Faktoren sind bei Patient:innen mit T2DM und MASLD mit signifikanter Leberfibrose assoziiert?
Methode
Retrospektive monozentrische Studie bei Erwachsenen im Nanjing Drum Tower Hospital von Januar 2018 bis Dezember 2025; Einschluss bei T2DM, MASLD und VCTE; multivariable logistische Regression nach multipler Imputation.
Ergebnisse
Unter 1.355 Patient:innen hatten 584 (43,10 %) eine signifikante Fibrose. Alter, CAP-Grad, AST, GGT und Hyperurikämie waren positiv assoziiert; BMI nicht unabhängig assoziiert (OR 1,034; 95 %-KI 0,993–1,077).
Einschränkungen
Beobachtungsstudie mit fehlenden Daten; für Medikamentenbefunde war der Zeitpunkt der Behandlung relativ zur VCTE nicht verfügbar.
Schlussfolgerung der Autor:innen
Alter, CAP-Grad, Transaminasen, GGT und Hyperurikämie waren bei Patient:innen mit T2DM und MASLD mit signifikanter Fibrose assoziiert. Medikamentenbezogene Assoziationen müssen prospektiv bestätigt werden.
Kernaussagen
- 584 von 1.355 Patient:innen hatten signifikante Fibrose
- Alter, CAP-Grad, AST, GGT und Hyperurikämie waren positiv assoziiert
- BMI war nicht unabhängig assoziiert (OR 1,034; 95 %-KI 0,993–1,077)
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Endocrinology, online erschienen am 03.11.2026. Verfasst von Yi Ding und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Nanjing Drum Tower Hospital, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Liver Cirrhosis, Fatty Liver. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Diabetes mellitus
Abstract (Originalsprache)
Background/aims To identify factors associated with significant liver fibrosis in patients with type 2 diabetes mellitus (T2DM) and metabolic dysfunction-associated steatotic liver disease (MASLD) and to inform clinical risk stratification.
Methods
We retrospectively included adults hospitalized in the Department of Endocrinology, Nanjing Drum Tower Hospital, from January 2018 to December 2025 who had T2DM, MASLD, and vibration-controlled transient elastography (VCTE). Significant fibrosis was defined as liver stiffness measurement ≥ 8 kPa. Missing data were handled by multiple imputation (five datasets). After multicollinearity assessment, variables were entered into a multivariable logistic regression model, with a sensitivity analysis substituting ALT for AST.
Results
Among 1355 patients, 584 (43.10%) had significant fibrosis. Age (OR = 1.036), CAP grade (S1: OR = 1.808; S2: OR = 2.597; S3: OR = 2.709), AST (OR = 1.025), GGT (OR = 1.006), and hyperuricemia (OR = 1.345) were positively associated with significant fibrosis. BMI was not independently associated (OR = 1.034, 95% CI 0.993–1.077). SGLT-2 inhibitor use was inversely associated (OR = 0.618), whereas glinide use was positively associated (OR = 2.524); these medication findings were exploratory because treatment timing relative to VCTE was unavailable. Diabetic macrovascular disease showed an inverse association (OR = 0.582) that should not be interpreted as protective. ALT remained positively associated in sensitivity analysis (OR = 1.014).
Conclusions
Age, CAP grade, transaminase levels, GGT, and hyperuricemia were associated with significant fibrosis in patients with T2DM and MASLD. Medication-related associations require prospective confirmation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacy, Nanjing Drum Tower Hospital, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China.
- Nanjing Drum Tower Hospital, Nanjing, China.
- Department of Pharmacy, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.
- Department of Endocrinology, Endocrine and Metabolic Disease Medical Center, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.
- Branch of National Clinical Research Centre for Metabolic Diseases, Nanjing, China.
Zitieren
APA
Ding, Y., Ma, X., Luo, Y., Zhou, Z., Li, L., Ge, Z., & Ji, C. (2026). Factors associated with significant liver fibrosis in patients with type 2 diabetes mellitus and metabolic dysfunction-associated steatotic liver disease: a single-center retrospective study. Frontiers in Endocrinology, 17. https://doi.org/10.3389/fendo.2026.2005171
Vancouver
Ding Y, Ma X, Luo Y, Zhou Z, Li L, Ge Z, et al. Factors associated with significant liver fibrosis in patients with type 2 diabetes mellitus and metabolic dysfunction-associated steatotic liver disease: a single-center retrospective study. Frontiers in Endocrinology. 2026;17. doi:10.3389/fendo.2026.2005171
BibTeX
@article{Ding2026,
author = {Ding, Yi and Ma, Xuerong and Luo, Yafei and Zhou, Zhuolin and Li, Lintong and Ge, Zhijuan and Ji, Cheng},
title = {Factors associated with significant liver fibrosis in patients with type 2 diabetes mellitus and metabolic dysfunction-associated steatotic liver disease: a single-center retrospective study},
journal = {Frontiers in Endocrinology},
year = {2026},
volume = {17},
doi = {10.3389/fendo.2026.2005171}
}
EUVIMED